Vitamin B3-related NAD+ precursor fact sheet
Nicotinamide riboside
Also known as NR, niagen
Nicotinamide riboside is converted through cellular pathways toward NAD+. Human trials usually show biomarker changes, while clinical outcomes remain mixed or negative.
Quick answer
Nicotinamide riboside can raise NAD-related biomarkers in people, but it is not an FDA-approved drug for aging, cognitive decline, mitochondrial disease, or fatigue. Biomarker movement should not be confused with proven health benefit.
By the PeptideFactSheets Editorial Team. Claims are source-checked under our editorial policy; clinician review is identified only when a named reviewer is shown.
What is Nicotinamide riboside?
Nicotinamide riboside is a vitamin B3-related compound and one of several precursors cells can use to make NAD+.
It is sold in dietary supplements, a category FDA does not approve for safety and effectiveness before marketing.
Why are people interested in it?
NR offers an oral way to influence NAD metabolism without administering NAD+ itself.
It is studied across metabolic, cardiovascular, muscle, neurological, and aging-related questions, but small trials and multiple endpoints make isolated positive signals easy to overinterpret.
Current regulatory status
No nicotinamide-riboside drug is FDA approved to prevent or treat aging, cognitive decline, mitochondrial dysfunction, or fatigue. Dietary-supplement marketing does not equal FDA approval.
What is it approved for?
No FDA-approved use. Commercial availability, supplement marketing, and clinical research do not equal an FDA-approved medicine.
What is it being studied for?
Evidence snapshot
Multiple human trials establish absorption and biomarker effects. Controlled studies have not yet established a durable, reproducible benefit on cognition, physical function, or major clinical outcomes.
Potential benefits being researched
- Trials commonly report increased blood NAD-related metabolites.
- A randomized pilot in mild cognitive impairment found target engagement but did not show a significant cognitive benefit over placebo.
A mechanism, biomarker, or secondary endpoint is not proof of a meaningful clinical benefit.
Known or possible risks
- Short controlled studies generally report acceptable tolerability, but they are not large or long enough to define uncommon harms.
- Supplement strength, purity, and labeling can vary, and FDA does not preapprove supplements for effectiveness.
- Long-term consequences of chronically altering NAD metabolism in diverse populations are uncertain.
What we still do not know
- Whether any biomarker change improves healthspan or disease outcomes
- Whether a specific deficient or disease-defined population benefits
- Long-term safety and clinically meaningful interactions
- How NR compares with NMN or lifestyle interventions on patient-centered outcomes
Plain-English takeaway
NR has credible human target-engagement data, but a higher NAD biomarker is a research result—not proof of better memory, energy, or longevity.
Research and reference links
Use these primary and authoritative sources to verify status and read beyond this summary. A study or registry entry does not by itself prove benefit.
- 1Randomized NR pilot in mild cognitive impairment
Placebo-controlled pilot reporting biomarker engagement without a significant cognitive benefit.
- 2Systematic review of NAD precursor trials
Review of human NR and NMN trials describing consistent biomarker effects and heterogeneous clinical outcomes.
- 3FDA GRAS notice response materials for NR chloride
Food-ingredient regulatory record; GRAS status is not approval of anti-aging or disease claims.
- 4FDA: what ‘FDA approved’ does and does not mean
FDA explains that dietary supplements are not approved for safety and effectiveness before marketing.